Evidence map›Paper›PMID 36121651›Full record

Trial reportInternational journal of cancer2023

First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.

Tianshu Liu, Yuxian Bai, Xiaoyan Lin, Wei Li, Jufeng Wang, Xiaochun Zhang, Hongming Pan, Chunmei Bai, Li Bai, Ying Cheng and 15 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 6 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 6 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Efficacy of ChemoimmunotherapyCurrent medicinal chemistry · 2024
    Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 20 institutions in 5 countries.

Tianshu LiuZhongshan Hospital Fudan University, Shanghai, China.ORCID 0000-0002-8604-6311
Yuxian BaiHerbin Medical University, Heilongjiang, China.
Xiaoyan LinFujian Medical University Union Hospital, Fuzhou, China.
Wei LiThe First Hospital of Jilin University, Changchun, China.
Jufeng WangThe Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Xiaochun ZhangThe Affiliated Hospital of Qingdao University, Qingdao, China.
Hongming PanSir Run Run Shaw Hospital, Hangzhou, China.
Chunmei BaiPeking Union Medical College Hospital, Beijing, China.ORCID 0000-0003-1333-9145
Li BaiChina P.L.A. General Hospital (301 Hospital), Beijing, China.
Ying ChengJilin Cancer Hospital, Changchun, China.
Jingdong ZhangLiaoning Cancer Hospital and Institute, Shenyang, China.ORCID 0000-0002-0711-2764
Haijun ZhongZhejiang Cancer Hospital, Hangzhou, China.
Yi BaTianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Wenwei HuThe First People's Hospital of Changzhou, Changzhou, China.
Ruihua XuMedical Oncology Cancer Center, Sun Yat-Sen University, Guangzhou, China.ORCID 0000-0001-9771-8534
Weijian GuoFudan University Shanghai Cancer Center, Shanghai, China.
Shukui QinEastern Theater General Hospital, QinHuai District Medical Area, China.ORCID 0000-0002-3414-2790
Nong YangHunan Cancer Hospital, Changsha Shi, China.
Jianwei LuJiangsu Cancer Hospital, Nanjing, China.
Kohei ShitaraNational Cancer Center Hospital East, Kashiwa, Japan.
Ming LeiBristol Myers Squibb, Princeton, New Jersey, USA.
Mingshun LiBristol Myers Squibb, Princeton, New Jersey, USA.
Nicole BaoBristol Myers Squibb, Princeton, New Jersey, USA.
Tian ChenBristol Myers Squibb, Princeton, New Jersey, USA.
Lin ShenDepartment of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.ORCID 0000-0002-8798-4756
Bristol-Myers Squibb (United States) · USSun Yat-sen University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNChinese PLA General Hospital · CNEastern Medical College and Hospital · BDFudan University Shanghai Cancer Center · CNFujian Medical University · CNHeilongjiang University · CNHunan Cancer Hospital · CNJiangsu Cancer Hospital · CNJilin Province Tumor Hospital · CNJilin University · CNLiaoning Cancer Hospital & Institute · CNNational Cancer Center Hospital East · JPPeking University · CNQingdao University · CNSir Run Run Shaw Hospital · CNThe First People's Hospital of Changzhou · CNTianjin Medical University Cancer Institute and Hospital · CNZhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC.

Indexed as

AdenocarcinomaEsophageal NeoplasmsStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsEast Asian PeopleEsophagogastric JunctionHumansIpilimumabNivolumabOxaliplatinIpilimumabNivolumabOxaliplatinAsian Continental Ancestry Groupgastrointestinal neoplasmsimmunotherapynivolumabstomach neoplasms

Identifiers

PMID36121651
PMCPMC10092493
OpenAlexW4296329502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.